article thumbnail

Pharmaceutical Manufacturing And Packaging Congress 2022 Connects Pharma Leaders

The Pharma Data

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) covers the current state of the pharmaceutical manufacturing and packaging industry. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies.

article thumbnail

Scandinavia: insight into opportunities for drug discovery

Drug Discovery World

A good part of half of those are within pharma. The weakness connected to that is we have so few large pharmaceuticals. Testa Center CEO Jesper Hedberg has been involved with the organisation since its inception and is a keen advocate of helping companies traverse the pharmaceutical development process.

Science 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. Each company will have its own processes, but they will all have the same result. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval.

article thumbnail

Case study: Extracting tidy data from Open Targets Genetics with Otargen

The Open Targets Blog

Amir has worked in the pharma/biotech sector for over ten years, using bioinformatics for data integration and multi-omics analysis for target identification and validation, and his team were an early adopter of Open Targets Genetics.  This is where our idea for an R package came from. 

article thumbnail

Reflections on life science’s regulatory environment  

Drug Discovery World

Remco Munnik (RM): Up to now, regulatory has always been the spider in the web within a pharmaceutical company – collecting all of the relevant information for submission of the registration: Clinical, CMC, administrative data, etc – then compiling a valid eCTD by the submission deadline.

article thumbnail

What it takes to make cancer research more inclusive

Drug Discovery World

In recent years, governments, institutes, pharma companies, and funding bodies have taken significant measures to proactively address cancer disparities. To resolve this discrepancy, pharma sponsors of clinical studies are now actively working towards decentralising trials to make patient participation easier.

Research 130
article thumbnail

Scaling Phage Therapy

Codon

3 Another considerable obstacle to pharmaceutical companies’ interest (and investment) is the fact that for a product to be patentable — and therefore profitable — it has to be considered new and inventive. I cover this more extensively in The Good Virus.

Therapies 138